Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies

Ghanizadeh, Ahmad, Singh, Ajeet B., Berk, Michael and Torabi-Nami, Mohammad 2015, Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies, Expert opinion on therapeutic targets, vol. 19, no. 7, pp. 1-13, doi: 10.1517/14728222.2015.1019866.

Attached Files
Name Description MIMEType Size Downloads

Title Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies
Author(s) Ghanizadeh, Ahmad
Singh, Ajeet B.ORCID iD for Singh, Ajeet B. orcid.org/0000-0002-0853-7959
Berk, MichaelORCID iD for Berk, Michael orcid.org/0000-0002-5554-6946
Torabi-Nami, Mohammad
Journal name Expert opinion on therapeutic targets
Volume number 19
Issue number 7
Start page 1
End page 13
Total pages 13
Publisher Taylor & Francis
Place of publication Oxford, Eng.
Publication date 2015-04-16
ISSN 1744-7631
Keyword(s) biomarker
bipolar disorder
folic acid
oxidative stress.
Summary Introduction: Homocysteine levels have been associated with major depression, but associations with bipolar disorder remain less clear. Some data suggest homocysteine levels have potential as a biomarker of treatment response; however the literature is mixed.

Areas covered
: Oxidized forms of homocysteine can be potentially neurotoxic leading to glutamate toxicity, apoptotic transformation and neurodegenerative processes. High homocysteine may be a risk biomarker for bipolar disorders, but the empirical base remains too weak for firm conclusions. This review discusses the current literature for homocysteine levels as a biomarker.

Expert opinion: It is premature to foreclose the utility of homocysteine levels as a biomarker for bipolar disorder due the methodological inadequacies in the existing literature. These methodological design issues include lack of control for the confounding variables of concurrent medication, phase of bipolar disorder, gender, age, nutritional status, thyroid, liver and renal function, smoking or lean body mass. Well-powered association studies with confounder control could help shed more light on the important clinical question of homocysteine's utility as a biomarker in bipolar disorder. Future experiments are needed to examine the outcome of interventions modulating homocysteine for treating bipolar disorder. Only prospective randomized control trials will provide definitive evidence of the utility of homocysteine as a biomarker or therapeutic target.
Language eng
DOI 10.1517/14728222.2015.1019866
Field of Research 110319 Psychiatry (incl Psychotherapy)
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2015, Informa UK
Persistent URL http://hdl.handle.net/10536/DRO/DU:30073837

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in TR Web of Science
Scopus Citation Count Cited 11 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 526 Abstract Views, 5 File Downloads  -  Detailed Statistics
Created: Mon, 15 Jun 2015, 16:17:59 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.